Comparative Pharmacology
Head-to-head clinical analysis: TASCENSO ODT versus VELSIPITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TASCENSO ODT versus VELSIPITY.
TASCENSO ODT vs VELSIPITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It binds to S1P receptors on lymphocytes, inducing internalization and degradation of the receptor, thereby preventing egress of lymphocytes from lymph nodes, reducing peripheral lymphocyte count and immune-mediated demyelination in the central nervous system.
Sphingosine 1-phosphate (S1P) receptor modulator; selectively binds to S1P receptor subtypes 1, 4, and 5, inhibiting lymphocyte egress from lymphoid tissues, thereby reducing circulating lymphocytes.
14 mg orally once daily, with or without food. Swallow whole; do not crush, chew, or dissolve.
0.23 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is 48-56 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 20 days. This long half-life allows for weekly oral dosing and requires a prolonged washout period before initiating other treatments.
Renal: ~80% unchanged; biliary/fecal: ~20% as metabolites.
Primarily eliminated via biliary/fecal route (approximately 70% as unchanged drug) and renal excretion (approximately 30% as unchanged drug and metabolites, with less than 1% as unchanged drug in urine).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator